^
Association details:
| Biomarker: | NF1 deletion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + AZ 628 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Excerpt:
Strikingly, we observed that some of the cell lines that exhibited resistance to the single agents but were synergistically inhibited by the combination also had an activating mutation in either KRAS (SW480, SW837, DLD1, HCT116, HCT15) or loss-of-function mutations in NF1 (LOXIMVI, HCT116, RKO, MeWo; Fig. 5A; ref. 24).
DOI:
10.1158/1535-7163.MCT-15-0136-T
